From: Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers
Experimental system | Approach | Key proteins | |
---|---|---|---|
Tumor ECM | EMT in murine cancer cells [24] | MS of subcellular fractions | Fibronectin, collagens, laminins |
Metastatic melanoma cells [26] | Secretome MS | Fibronectin, ECM1, SPARC, osteopontin | |
Hepatocarcinogenesis [29] | ECM MS | Collagen splice variants, nidogen, decorin, perlecan | |
Cell attachment to collagen [34] | Phosphoprotein analysis | DBF4, GRK6, PAK2, FAK/ PTK2 | |
Breast cancer metastasis [34] | MS | Cystatin-M | |
Tumor invasiveness [41] | Antibody libraries | hsp90α | |
Tumor-stroma interactions | Tumor versus normal stroma [45] | Laser capture + MS | CapG (actin-regulating protein) |
CAFs [49] | MS of cell lysates | Caveolin-1 | |
MMP7 effect of CAFs [50] | MS of cell lysates | IGFBP5 | |
Lung cancer TME [54] | Cytokine assays | CXCL1, IL-18 | |
Stromal cell secretome [60] | Antibody arrays | HGF | |
Immune cells in the tumor microenvironment | Mesothelioma effusions [67] | Antibody arrays | HGF, MIP-1d, MIP-3a, NAP-2 |
Ovarian tumor macrophages [68] | MS of supernatants | 14-3-3 zeta | |
CD45RA + versus CD45RO + T cells [70] | MS of cell lysates | Cell redox proteins | |
MDSCs + IL1B [72] | MS of cell lysates | FAS pathway and caspase network |